These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 24942808)

  • 1. Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action.
    Patrignani P; Tacconelli S; Piazuelo E; Di Francesco L; Dovizio M; Sostres C; Marcantoni E; Guillem-Llobat P; Del Boccio P; Zucchelli M; Patrono C; Lanas A
    J Thromb Haemost; 2014 Aug; 12(8):1320-30. PubMed ID: 24942808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.
    Capone ML; Tacconelli S; Sciulli MG; Grana M; Ricciotti E; Minuz P; Di Gregorio P; Merciaro G; Patrono C; Patrignani P
    Circulation; 2004 Mar; 109(12):1468-71. PubMed ID: 15037526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects.
    Maenthaisong R; Tacconelli S; Sritara P; Del Boccio P; Di Francesco L; Sacchetta P; Archararit N; Aryurachai K; Patrignani P; Suthisisang C
    Int J Immunopathol Pharmacol; 2013; 26(2):403-17. PubMed ID: 23755755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes.
    Cerletti C; Dell'Elba G; Manarini S; Pecce R; Di Castelnuovo A; Scorpiglione N; Feliziani V; de Gaetano G
    Clin Pharmacokinet; 2003; 42(12):1059-70. PubMed ID: 12959636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial to assess the pharmacodynamics and pharmacokinetics of a single dose of an extended-release aspirin formulation.
    Patrick J; Dillaha L; Armas D; Sessa WC
    Postgrad Med; 2015 Aug; 127(6):573-80. PubMed ID: 25998572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacology of platelet cyclooxygenase inhibition.
    Patrono C; Ciabattoni G; Patrignani P; Pugliese F; Filabozzi P; Catella F; Davì G; Forni L
    Circulation; 1985 Dec; 72(6):1177-84. PubMed ID: 3933848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining platelet response to acetylsalicylic acid: the relation between inhibition of serum thromboxane B
    Gurbel PA; Bliden KP; Tantry US
    J Thromb Thrombolysis; 2021 Feb; 51(2):260-264. PubMed ID: 33170486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New direct and indirect methods for the detection of cyclooxygenase 1 acetylation by aspirin; the lack of aspirin resistance among healthy individuals.
    Kovács EG; Katona E; Bereczky Z; Homoródi N; Balogh L; Tóth E; Péterfy H; Kiss RG; Edes I; Muszbek L
    Thromb Res; 2013 Apr; 131(4):320-4. PubMed ID: 23422285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus.
    Bhatt DL; Grosser T; Dong JF; Logan D; Jeske W; Angiolillo DJ; Frelinger AL; Lei L; Liang J; Moore JE; Cryer B; Marathi U
    J Am Coll Cardiol; 2017 Feb; 69(6):603-612. PubMed ID: 28089180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study.
    Franchi F; Schneider DJ; Prats J; Fan W; Rollini F; Been L; Taatjes-Sommer HS; Bhatt DL; Deliargyris EN; Angiolillo DJ
    J Thromb Thrombolysis; 2022 Oct; 54(3):373-381. PubMed ID: 36036856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclooxygenase expression and platelet function in healthy dogs receiving low-dose aspirin.
    Dudley A; Thomason J; Fritz S; Grady J; Stokes J; Wills R; Pinchuk L; Mackin A; Lunsford K
    J Vet Intern Med; 2013; 27(1):141-9. PubMed ID: 23278865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization.
    Frelinger AL; Li Y; Linden MD; Barnard MR; Fox ML; Christie DJ; Furman MI; Michelson AD
    Circulation; 2009 Dec; 120(25):2586-96. PubMed ID: 19996015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
    Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obesity is associated with impaired responsiveness to once-daily low-dose aspirin and in vivo platelet activation.
    Petrucci G; Zaccardi F; Giaretta A; Cavalca V; Capristo E; Cardillo C; Pitocco D; Porro B; Schinzari F; Toffolo G; Tremoli E; Rocca B
    J Thromb Haemost; 2019 Jun; 17(6):885-895. PubMed ID: 30933424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of laboratory methods routinely used to detect the effect of aspirin against new reference methods.
    Kovács EG; Katona É; Bereczky Z; Homoródi N; Balogh L; Tóth E; Péterfy H; Kiss RG; Édes I; Muszbek L
    Thromb Res; 2014 May; 133(5):811-6. PubMed ID: 24207016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100.
    Homoncik M; Jilma B; Hergovich N; Stohlawetz P; Panzer S; Speiser W
    Thromb Haemost; 2000 Feb; 83(2):316-21. PubMed ID: 10739392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing aspirin dose for colorectal cancer patients through deep phenotyping using novel biomarkers of drug action.
    Patrignani P; Tacconelli S; Contursi A; Piazuelo E; Bruno A; Nobili S; Mazzei M; Milillo C; Hofling U; Hijos-Mallada G; Sostres C; Lanas A
    Front Pharmacol; 2024; 15():1362217. PubMed ID: 38495101
    [No Abstract]   [Full Text] [Related]  

  • 18. Thromboxane A(2) generation, in the absence of platelet COX-1 activity, in patients with and without atherothrombotic myocardial infarction.
    DeFilippis AP; Oloyede OS; Andrikopoulou E; Saenger AK; Palachuvattil JM; Fasoro YA; Guallar E; Blumenthal RS; Kickler TS; Jaffe AS; Gerstenblith G; Schulman SP; Rade JJ
    Circ J; 2013; 77(11):2786-92. PubMed ID: 23985963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced Variability to Aspirin Antiplatelet Effect by the Coadministration of Statins in High-Risk Patients for Cardiovascular Disease.
    Tacconelli S; Dovizio M; Di Francesco L; Meneguzzi A; D'Agostino I; Evangelista V; Manarini S; Capone ML; Grossi L; Porreca E; Di Febbo C; Bruno A; Ballerini P; Levantesi G; Fava C; Minuz P; Patrignani P
    Clin Pharmacol Ther; 2018 Jul; 104(1):111-119. PubMed ID: 29574792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human pharmacology of naproxen sodium.
    Capone ML; Tacconelli S; Sciulli MG; Anzellotti P; Di Francesco L; Merciaro G; Di Gregorio P; Patrignani P
    J Pharmacol Exp Ther; 2007 Aug; 322(2):453-60. PubMed ID: 17473175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.